Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 3/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21242477 | 0.80 | NOS1 (0.55) | CSNK2A1MAPK14BACE1NOS1LIMK1 | |
| SCHEMBL17889606 | 0.75 | MAPK14 (0.61) | CSNK2A1MAPK14NOS1LIMK1HDAC1 | |
| SCHEMBL11996720 | 0.73 | ADORA2A (0.40) | MAPK14HDAC1NPC1MAPTRAB9A | |
| SCHEMBL25377978 | 0.72 | BACE1 (0.41) | CSNK2A1MAPK14BACE1NOS1LIMK1 | |
| SCHEMBL30482478 | 0.72 | BACE1 (0.41) | CSNK2A1MAPK14BACE1NOS1LIMK1 | |
| SCHEMBL69900 | 0.71 | CSNK2A1 (0.62) | CSNK2A1MAPK14BACE1LIMK1ALDH1A1 | |
| SCHEMBL15641472 | 0.71 | CYP2A6 (0.59) | CSNK2A1LIMK1HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL30279938 | 0.71 | CYP2A6 (0.59) | CSNK2A1LIMK1HDAC1ALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL31452773 | 0.70 | CYP2A6 (0.58) | CSNK2A1LIMK1HDAC1ALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL22834317 | 0.70 | CSNK2A1 (0.61) | CSNK2A1MAPK14BACE1LIMK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3025724-B1 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | UNIV NORTH CAROLINA CHAPEL HILL (US) | 2018-07-11 | — | — | EP | claimed |
| US-9808461-B2 | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-11-07 | — | — | US | claimed |
| EP-3025724-A1 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | The University of North Carolina At Chapel Hill (US) | 2016-06-01 | — | — | EP | claimed |
| EP-2429566-B1 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | UNIV NORTH CAROLINA (US) | 2016-01-06 | — | — | EP | claimed |
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | claimed |
| US-20130303543-A1 | PROTECTION OF RENAL TISSUES FROM ISCHEMIA THROUGH INHIBITION OF THE PROLIFERATIVE KINASES CDK4 AND CDK6 | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-11-14 | — | — | US | claimed |
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | claimed |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF | 2011-09-15 | — | — | US | claimed |
| EP-2341911-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | claimed |
| EP-2341906-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | The University of North Carolina At Chapel Hill (US) | 2011-07-13 | — | — | EP | claimed |
| WO-2010039997-A9 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-05 | — | — | WO | claimed |
| WO-2010051127-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-06 | — | — | WO | claimed |
| WO-2010039997-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-04-08 | — | — | WO | claimed |
| EP-4709853-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024235844-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-11-21 | — | — | WO | disclosed |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2010039997-A9 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2010132725-A2 | CYCLIN DEPENDENT KINASE INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010051127-A2 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2010039997-A2 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224227-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CSNK2A1 664/4885MAPK14 370/4885BACE1 4795/4885 |
| US-20130303543-A1 | PROTECTION OF RENAL TISSUES FROM ISCHEMIA THROUGH INHIBITION OF THE PROLIFERATIVE KINASES CDK4 AND CDK6 | CDK4, CDK6, CDK3 | CSNK2A1 435/4885MAPK14 995/4885BACE1 3955/4885 |
| US-20110224221-A1 | HEMATOPOIETIC PROTECTION AGAINST IONIZING RADIATION USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK4, CDK6, CDKN1A | CSNK2A1 1010/4885MAPK14 414/4885BACE1 4574/4885 |
| US-20150111896-A1 | HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS | CDK6, CDK4, CDKN1A | CSNK2A1 664/4885MAPK14 370/4885BACE1 4795/4885 |
| US-20220280519-A1 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | MCL1, MPL, BCL9 | CSNK2A1 1336/4885MAPK14 2298/4885BACE1 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.